Toyota Tsusho stock falls 3 percent. CFAO buys Medswana

Published on 10/08/2026 at 03:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Toyota Tsusho stock was last at JPY 7,186 on October 8, 2026, while CFAO expanded its African healthcare network. Eight analysts set an average target of JPY 8,378.8.

Toyota Tsusho, JP3635000007, Illustration mit AI erstellt.

Toyota Tsusho stock (ISIN JP3635000007) was trading at JPY 7,186 on the Tokyo Stock Exchange on October 8, 2026 at 10:00 a.m. JST, down 3.00 percent from the prior close. The group's CFAO unit acquired 75 percent of Botswana pharmaceutical wholesaler Medswana and added Madagascar's Opham as a subsidiary on October 6, 2026, according to Vermoegenszentrum.

CFAO widens healthcare network

The transaction gives Toyota Tsusho's healthcare platform a larger Southern African footprint. Medswana is a pharmaceutical wholesaler in Botswana, while Opham operates in Madagascar, and both businesses were brought into the group through CFAO's expansion.

The acquisition adds distribution assets rather than a disclosed earnings contribution. That distinction matters for Toyota Tsusho stock because the release describes network expansion, but it does not publish a purchase price or profit forecast for the acquired companies.

Consensus target stays above the quote

Investing.com lists a Buy consensus from eight analysts, with six Buy ratings, two Holds and zero Sells. The average 12-month target is JPY 8,378.8, with a high of JPY 10,300 and a low of JPY 7,100, according to Investing.com.

Against the JPY 7,186 quote on October 8, 2026, the average target lies 16.6 percent above the price. The low target is JPY 7,100, leaving the current quote 1.2 percent above that lower analyst estimate.

Stock remains below yearly high

Toyota Tsusho stock traded between JPY 7,123 and JPY 7,387 during the October 8 session, with volume of 519,700 shares. Its 52-week range was JPY 4,210 to JPY 7,798, putting the latest price 7.85 percent below the yearly high.

Market capitalization stood at JPY 7.6 trillion as of October 8, 2026. The combination of a 3.00 percent daily decline, a new healthcare expansion and an average analyst target above the quote leaves the market reaction separate from the strategic rationale of the transaction.